Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (301-310 of 315) with videos related to

Pageof 32
Sort By:
Hepatology (Baltimore, Md.)|December 28, 2019
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ CellsPietro Carotenuto, Somaieh Hedayat, Matteo Fassan, et al.
Nature Medicine|January 22, 2019
Small-molecule targeting of brachyury transcription factor addiction in chordomaTanaz Sharifnia, Mathias J Wawer, Ting Chen, et al.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Cancer Research|April 17, 2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasisSuzanne A Eccles, Andy Massey, Florence I Raynaud, et al.
Nature Communications|November 19, 2021
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damagePietro Carotenuto, Francesco Amato, Andrea Lampis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer GrowthJonathan Welti, Denisa Bogdan, Ines Figueiredo, et al.
Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.
Cancer Research|November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate CancerVeronica Gil, Susana Miranda, Ruth Riisnaes, et al.
Science (New York, N.Y.)|February 24, 2018
Patient-derived organoids model treatment response of metastatic gastrointestinal cancersGeorgios Vlachogiannis, Somaieh Hedayat, Alexandra Vatsiou, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Pageof 32

Showing results (301-310 of 315) with videos related to

Sort By:
Pageof 32
Hepatology (Baltimore, Md.)|December 28, 2019
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ CellsPietro Carotenuto, Somaieh Hedayat, Matteo Fassan, et al.
Nature Medicine|January 22, 2019
Small-molecule targeting of brachyury transcription factor addiction in chordomaTanaz Sharifnia, Mathias J Wawer, Ting Chen, et al.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Cancer Research|April 17, 2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasisSuzanne A Eccles, Andy Massey, Florence I Raynaud, et al.
Nature Communications|November 19, 2021
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damagePietro Carotenuto, Francesco Amato, Andrea Lampis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer GrowthJonathan Welti, Denisa Bogdan, Ines Figueiredo, et al.
Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.
Cancer Research|November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate CancerVeronica Gil, Susana Miranda, Ruth Riisnaes, et al.
Science (New York, N.Y.)|February 24, 2018
Patient-derived organoids model treatment response of metastatic gastrointestinal cancersGeorgios Vlachogiannis, Somaieh Hedayat, Alexandra Vatsiou, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Pageof 32